3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Failure
1
Hepatitis C
1
Hepatitis B
1
Hepatic Insufficiency
1
HIV Infections
1
Carcinoma, Hepatocellular
1
Interventions
Capecitabine
5
Bevacizumab
5
Radiotherapy
3
Oxaliplatin
3
olaparib
2
durvalumab
2
darolutamide
2
dalpiciclib
2
atezolizumab
2
apatinib
2
anlotinib
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiosurgery
2
Leucovorin
2
Laparoscopy
2
Immunotherapy
2
Fluorouracil
2
Drug Therapy
2
trametinib
1
toripalimab
1
tislelizumab
1
spartalizumab
1
pyrotinib
1
pomalidomide
1
palbociclib
1
nilotinib
1
ledipasvir, sofosbuvir drug combination
1
ledipasvir
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Raltegravir Potassium
×
90 days
×
Clear all
NCT01022476
2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2
Completed
14 enrolled